Bafiertam Side Effects
Generic name: monomethyl fumarate
Medically reviewed by Drugs.com. Last updated on Dec 2, 2024.
Note: This document provides detailed information about Bafiertam Side Effects associated with monomethyl fumarate. Some dosage forms listed on this page may not apply specifically to the brand name Bafiertam.
Applies to monomethyl fumarate: oral capsule delayed release.
Common side effects of Bafiertam
Some side effects of monomethyl fumarate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
Less common side effects
- belching
- heartburn
- indigestion
- stomach discomfort or upset
Serious side effects of Bafiertam
Along with its needed effects, monomethyl fumarate (the active ingredient contained in Bafiertam) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking monomethyl fumarate:
Less common side effects
Incidence not known
- chest tightness
- dark urine
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- loss of appetite
- painful blisters on trunk of body
- right upper stomach tenderness
- trouble with breathing
- unusual tiredness or weakness
- weight loss
- yellow eyes or skin
For healthcare professionals
Applies to monomethyl fumarate: oral delayed release capsule.
Hematologic adverse events
- Common (1% to 10%): Lymphopenia[Ref]
Hypersensitivity
- Frequency not reported: Anaphylaxis, angioedema[Ref]
Immunologic
- Frequency not reported: Herpes zoster, disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, herpes zoster meningomyelitis, herpes simplex virus, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis)[Ref]
Genitourinary
- Common (1% to 10%): Albumin urine present[Ref]
Hepatic
- Common (1% to 10%): Aspartate aminotransferase increased
- Frequency not reported: Liver injury[Ref]
Nervous system
- Frequency not reported: Progressive Multifocal Leukoencephalopathy (PML)[Ref]
Cardiovascular
- Very common (10% or more): Flushing (40%)[Ref]
Dermatologic
Gastrointestinal
- Very common (10% or more): Abdominal pain (18%), diarrhea (14%), nausea (12%)
- Common (1% to 10%): Vomiting, dyspepsia[Ref]
References
1. (2020) "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company
Frequently asked questions
More about Bafiertam (monomethyl fumarate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Bafiertam side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.